AstraZeneca, the Anglo-Swedish pharmaceutical giant, is building a research and development center in Hong Kong. The new center will be focusing on cell and gene therapy drugs. Set to be completed by end-2024, it will be the first such center for a top-ten pharmaceutical company in Hong Kong.
With an initial workforce of 100 employees, AstraZeneca aims to explore treatments for autoimmune diseases, oncology, and rare diseases.
The move aligns with a broader initiative involving over 30 companies investing approximately US$4 billion in Hong Kong. It aligns with the Hong Kong government’s campaign ‘Office for Attracting Strategic Enterprises’ that was launched earlier this year.
Source: bioprocessintl.com
